A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects

This 2018 pilot study assessed the safety and feasibility of daily 1 mg rapamycin administration over 8 weeks in 25 healthy older adults aged 70–95. The treatment was generally well-tolerated, with minor adverse events including facial rash, stomatitis, and gastrointestinal discomfort. Notably, there were statistically significant reductions in erythrocyte parameters